Peptide
Orforglipron
Oral GLP-1 breakthrough
A non-peptide oral GLP-1 receptor agonist representing a breakthrough in convenient metabolic therapy. Provides GLP-1 benefits without injection.
Mechanisms
- Oral GLP-1 agonism
- Convenient dosing
- Weight management
- Glucose control
Dosing
Typical dose
12–45mg
Timing
Daily oral administration. Major advance in GLP-1 convenience.